BioNTech Expects Omicron COVID-19 Adapted Vaccine Deliveries by October 2022

BioNTech, a German biotech company, said it is expecting to start deliveries of two Omicron-adapted vaccines as soon as October 2022, which will help the growing demand in the fourth quarter of 2022.

The demand for the COVID-19 vaccine, and 3.6 doses of which have been shipped across the globe, is currently waning as most people in the western countries have received three or four shots of the vaccine already.

Although, the Coronavirus booster campaigns using upgraded shots specifically targeting the Omicron Coronavirus variant are expected to increase the demand in autumn. BioNTech said the pending regulatory approval, and both of its adapted vaccines will be available in time for the campaigns.

The revenue and net profit of second-quarter both has dropped by around 40 percent from a year earlier, to 3.2 billion euros and 1.672 billion euros, respectively. BioNTech has reaffirmed its 2022 vaccine revenue guidance of 13 billion euros to 17 billion euros, which is dropped from 19 billion euros in 2021.

Jens Holstein, chief financial officer of BioNTech, said with their strong reaffirmed year to date, and they believe to be well on track to achieve their past financial guidance for the ongoing financial year. He also said with their initiatives around the Coronavirus vaccine candidates adapted by Omicron variant, and they also expect an uptake in demand in their main markets in the fourth quarter of 2022.